Zydus Cadila has received tentative approval for Losartan Potassium Tablets in the strengths of 25 mg, 50 mg and 100 mg from the USFDA. The branded sales of Losartan Potassium Tablets, which falls in the anti-hypertensive segment, is estimated at USD 817 million in 2006 as per NDC Health.
The group now has 23 approvals since the commencement of filing process in FY 2003-04. Currently the group markets 9 generics through its subsidiary Zydus Pharmaceuticals (USA) Inc
